This study focuses on people with Hereditary Angioedema, a rare genetic condition that causes unexpected episodes of severe swelling in various parts of the body. The research evaluates a new oral medication called deucrictibant, which is being tested as a preventive treatment to reduce the frequency of swelling attacks. The study will compare deucrictibant extended-release tablets to a placebo in adolescents and adults.
The study will test if taking a 40 mg tablet of deucrictibant daily can prevent or reduce the occurrence of swelling attacks compared to taking a placebo. For comparison purposes, some participants will also have access to icatibant, an already approved medication that is injected under the skin to treat acute attacks when they occur.
The treatment period will last 24 weeks, during which participants will take either deucrictibant or placebo tablets. Throughout the study, participants will need to keep track of any swelling attacks they experience and may use emergency treatment if needed. The study will monitor how well the medication works and check for any potential side effects through regular health assessments.
Bulgaria 
France 
Germany 
Hungary 
Ireland 
Italy 
Poland 
Romania 
Slovakia 
Spain 
